Skip to main content
REGN
NASDAQ Life Sciences

FDA 批准雷根诺的遗传性听力丧失基因治疗

feedReported by Reuters
Sentiment info
Positive
Importance info
8
Price
$763.24
Mkt Cap
$80.676B
52W Low
$476.487
52W High
$821.11
Market data snapshot near publication time

summarizeSummary

美国食品和药物管理局（FDA）已经批准了雷根诺针对一种罕见的遗传性听力丧失的基因治疗。这一批准标志着雷根诺产品组合在基因治疗领域和新的适应症方面取得了重大扩展。这是在该公司最近取得的一系列积极发展之后，包括最近FDA和欧盟对杜必妥的批准以及塞姆地司兰的III期试验取得积极结果。这种新疗法可能会提供一种新的收入来源，并进一步使公司的产品多样化，超越其现有的畅销药。交易者将会关注这款新治疗方法的商业推出和市场渗透的详细信息。

在该公告发布时，REGN的交易价格为$763.24，交易所为NASDAQ，所属行业为Life Sciences，市值约为$806.8亿。 52周交易区间为$476.49至$821.11。 这则新闻被评估为积极市场情绪，重要性评分为8/10。 来源：Reuters。

show_chartPrice Chart

Share this article

Copied!

feed REGN - Latest Insights

REGN
Apr 29, 2026, 6:54 AM EDT
Filing Type: 10-Q
Importance Score:
8
Regeneron Reports Mixed Q1 Results, Authorizes $3B Buyback, Details Government Pricing Deals & Key Legal Updates
Sentiment: Neutral
View Wiseek Article
REGN
Apr 29, 2026, 6:50 AM EDT
Filing Type: 8-K
Importance Score:
8
Regeneron Reports Strong Q1 Results, Authorizes New $3.0 Billion Share Repurchase, and Secures Strategic Government Pricing Agreement
Sentiment: Positive
View Wiseek Article
REGN
Apr 29, 2026, 6:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Regeneron Posts 19% Revenue Growth in Q1, Non-GAAP EPS Up 15% Amidst GAAP Decline
Sentiment: Positive
View Wiseek Article
REGN
Apr 24, 2026, 12:25 AM EDT
Source: dpa-AFX
Importance Score:
8
Regeneron's Otarmeni Gene Therapy Approved by FDA for Genetic Hearing Loss
Sentiment: Positive
View Wiseek Article
REGN
Apr 23, 2026, 12:42 PM EDT
Source: Reuters
Importance Score:
8
FDA Approves Regeneron's Gene Therapy for Inherited Deafness
Sentiment: Positive
View Wiseek Article
REGN
Apr 23, 2026, 1:30 AM EDT
Source: Reuters
Importance Score:
7
Dupixent Sales Soar 30.8%, Beating Estimates in Sanofi's Q1 Report
Sentiment: Positive
View Wiseek Article
REGN
Apr 22, 2026, 5:30 PM EDT
Source: GlobeNewswire
Importance Score:
8
Dupixent Gains U.S. Approval for Young Children with Chronic Spontaneous Urticaria
Sentiment: Positive
View Wiseek Article
REGN
Apr 21, 2026, 10:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Regeneron's Cemdisiran Phase 3 Data Published, Regulatory Filing Submitted for gMG
Sentiment: Positive
View Wiseek Article
REGN
Apr 13, 2026, 1:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Dupixent Secures EU Approval for Young Children with Chronic Urticaria, Expanding Key Market
Sentiment: Positive
View Wiseek Article
REGN
Apr 12, 2026, 7:08 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Regeneron Forms Radiopharma Partnership with Telix, Potentially Worth Over $2.1 Billion
Sentiment: Positive
View Wiseek Article